Treatment of factor VIII inhibitors: products and strategies.
Treatment of patients with inhibitors to FVIII remains a complex clinical problem. Although characterizing the individual patient may aid in the initial development of a care plan, no treatment is uniformly reliable for all patients. Experts in the field are as likely to disagree as agree when it comes to choosing treatment options; few randomized clinical trials exist on which to base decisions.
Macik
B G
BG
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000276:immunology* / Q000627:therapeutic use; D006470:Hemorrhage / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood / Q000276:immunology
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D005169:Factor VIII